The REVEAL study has been assessing the sensitivity and specificity of iodine 124 evuzamitide (I 124 evuzamitide), a PET agent capable of visualizing signs of cardiac amyloidosis on imaging.
Kevin Accola, MD, spoke to Cardiovascular Business about new 10-year data on the performance of surgical valves featuring Resilia tissue. The findings are good news for Edwards Lifesciences, which also includes the tissue on many of its TAVR devices.
Matthew Reynolds, MD, Lahey Hospital and Medical Center, explains data from the EXCALIBER and CAMELOT studies that show ambulatory cardiac monitoring usage among more than 300,000 patients.
Gene manipulation can revert the cardiomyocytes back to a fetal state, allowing them to regenerate. Researchers are now looking for drugs to mimic the effect.
The publication will include "pictorial essays, case reports and expert commentary for today’s practicing radiologists," the society announced Thursday.
Early detection of cardiac amyloidosis is leads to the best outcomes, but it is often missed until later stages. AI is being developed to help detect these patients earlier using ECG and echo.
Researchers explored data from 23 different studies, identifying a “positive and almost linear association” between alcohol consumption and hypertension.
A new study suggests sildenafil, known by its brand name Viagra, can improve cerebrovascular function and minimize the risk of cognitive impairment caused by small vessel disease.
Paul Zei, MD, discusses late-breaking data from the REAL-AF Registry, which looked at the short- and long-term outcomes of radiofrequency ablation in paroxysmal and persistent atrial fibrillation.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/top_stories/public/2024-09/istock-1209664264.jpg.webp?itok=gQInU1vO)
